{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T14:52:04Z","timestamp":1782226324292,"version":"3.54.5"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"The Hebei Natural Science Foundation","award":["H2021206441"],"award-info":[{"award-number":["H2021206441"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-02689-8","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T11:03:55Z","timestamp":1749207835000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Obese patients with malignant tumor: a case series and literature review"],"prefix":"10.1007","volume":"16","author":[{"given":"Ping","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-yuan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruixia","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyu","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-lei","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,6]]},"reference":[{"issue":"10113","key":"2689_CR1","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1016\/S0140-6736(17)32129-3","volume":"390","author":"Worldwide trends in body-mass index","year":"2017","unstructured":"Worldwide trends in body-mass index. underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128\u00b79 million children, adolescents, and adults. Lancet. 2017;390(10113):2627\u201342.","journal-title":"Lancet"},{"issue":"17","key":"2689_CR2","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1056\/NEJMoa021423","volume":"348","author":"EE Calle","year":"2003","unstructured":"Calle EE, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348(17):1625\u201338.","journal-title":"N Engl J Med"},{"issue":"9612","key":"2689_CR3","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S0140-6736(08)60269-X","volume":"371","author":"AG Renehan","year":"2008","unstructured":"Renehan AG, et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371(9612):569\u201378.","journal-title":"Lancet"},{"issue":"02","key":"2689_CR4","first-page":"14","volume":"10","author":"W Zixian","year":"2012","unstructured":"Zixian W. Rational dose of chemotherapy for adult obese cancer patients. J China Prescrip Drug. 2012;10(02):14\u20138.","journal-title":"J China Prescrip Drug"},{"issue":"1","key":"2689_CR5","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ygyno.2015.04.002","volume":"138","author":"NS Horowitz","year":"2015","unstructured":"Horowitz NS, Wright AA. Impact of obesity on chemotherapy management and outcomes in women with gynecologic malignancies. Gynecol Oncol. 2015;138(1):201\u20136.","journal-title":"Gynecol Oncol"},{"issue":"9","key":"2689_CR6","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1345\/aph.19381","volume":"34","author":"MP Pai","year":"2000","unstructured":"Pai MP, Paloucek FP. The origin of the \u201cideal\u201d body weight equations. Ann Pharmacother. 2000;34(9):1066\u20139.","journal-title":"Ann Pharmacother"},{"issue":"4","key":"2689_CR7","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1200\/JOP.2012.000623","volume":"8","author":"JJ Griggs","year":"2012","unstructured":"Griggs JJ, et al. Appropriate chemotherapy dosing for obese adult patients with cancer: american society of clinical oncology clinical practice guideline. J Oncol Pract. 2012;8(4):e59\u201361.","journal-title":"J Oncol Pract"},{"issue":"11","key":"2689_CR8","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1001\/archinte.165.11.1267","volume":"165","author":"JJ Griggs","year":"2005","unstructured":"Griggs JJ, Sorbero ME, Lyman GH. Undertreatment of obese women receiving breast cancer chemotherapy. Arch Intern Med. 2005;165(11):1267\u201373.","journal-title":"Arch Intern Med"},{"issue":"11","key":"2689_CR9","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1200\/JCO.1996.14.11.3000","volume":"14","author":"GL Rosner","year":"1996","unstructured":"Rosner GL, et al. Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from cancer and leukemia group B study 8541. J Clin Oncol. 1996;14(11):3000\u20138.","journal-title":"J Clin Oncol"},{"issue":"18","key":"2689_CR10","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1200\/JCO.21.00471","volume":"39","author":"JJ Griggs","year":"2021","unstructured":"Griggs JJ, et al. Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO Guideline Update. J Clin Oncol. 2021;39(18):2037\u201348.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2689_CR11","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1186\/s12916-024-03688-2","volume":"22","author":"W Nie","year":"2024","unstructured":"Nie W, et al. Obesity and survival in advanced non-small cell lung cancer patients treated with chemotherapy, immunotherapy, or chemoimmunotherapy: a multicenter cohort study. BMC Med. 2024;22(1):463.","journal-title":"BMC Med"},{"issue":"1","key":"2689_CR12","doi-asserted-by":"crossref","first-page":"28","DOI":"10.21147\/j.issn.1000-9604.2022.01.03","volume":"34","author":"J Lu","year":"2022","unstructured":"Lu J, et al. Equivalent efficacy assessment of QL1101 and bevacizumab in nonsquamous non-small cell lung cancer patients: a two-year follow-up data update. Chin J Cancer Res. 2022;34(1):28\u201339.","journal-title":"Chin J Cancer Res"},{"issue":"3","key":"2689_CR13","doi-asserted-by":"crossref","first-page":"816","DOI":"10.20892\/j.issn.2095-3941.2020.0212","volume":"18","author":"T Chu","year":"2021","unstructured":"Chu T, et al. Equivalent efficacy study of QL1101 and bevacizumab on untreated advanced non-squamous non-small cell lung cancer patients: a phase 3 randomized, double-blind clinical trial. Cancer Biol Med. 2021;18(3):816\u201324.","journal-title":"Cancer Biol Med"},{"issue":"4","key":"2689_CR14","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41587-021-01070-8","volume":"40","author":"D Chowell","year":"2022","unstructured":"Chowell D, et al. Improved prediction of immune checkpoint blockade efficacy across multiple cancer types. Nat Biotechnol. 2022;40(4):499\u2013506.","journal-title":"Nat Biotechnol"},{"issue":"5","key":"2689_CR15","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-2600(23)00431-9","volume":"12","author":"H Zhong","year":"2024","unstructured":"Zhong H, et al. First-line penpulimab combined with paclitaxel and carboplatin for metastatic squamous non-small-cell lung cancer in China (AK105-302): a multicentre, randomised, double-blind, placebo-controlled phase 3 clinical trial. Lancet Respir Med. 2024;12(5):355\u201365.","journal-title":"Lancet Respir Med"},{"issue":"12","key":"2689_CR16","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1002\/ijc.34508","volume":"152","author":"ES Cheng","year":"2023","unstructured":"Cheng ES, et al. Female reproductive and hormonal factors and lung cancer mortality among never-smokers: a prospective cohort study of 287 408 Chinese women. Int J Cancer. 2023;152(12):2528\u201340.","journal-title":"Int J Cancer"},{"issue":"1","key":"2689_CR17","doi-asserted-by":"crossref","first-page":"98","DOI":"10.4103\/aja202212","volume":"25","author":"X Lv","year":"2023","unstructured":"Lv X, et al. Associations of sex hormone levels with body mass index (BMI) in men: a cross-sectional study using quantile regression analysis. Asian J Androl. 2023;25(1):98\u2013102.","journal-title":"Asian J Androl"},{"issue":"2","key":"2689_CR18","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2165\/11318100-000000000-00000","volume":"49","author":"MJ Hanley","year":"2010","unstructured":"Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet. 2010;49(2):71\u201387.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"2689_CR19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1021\/js980173a","volume":"88","author":"RA Blouin","year":"1999","unstructured":"Blouin RA, Warren GW. Pharmacokinetic considerations in obesity. J Pharm Sci. 1999;88(1):1\u20137.","journal-title":"J Pharm Sci"},{"issue":"6","key":"2689_CR20","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1517\/17425255.2011.570331","volume":"7","author":"GA Morrish","year":"2011","unstructured":"Morrish GA, Pai MP, Green B. The effects of obesity on drug pharmacokinetics in humans. Expert Opin Drug Metab Toxicol. 2011;7(6):697\u2013706.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"3","key":"2689_CR21","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S1470-2045(18)30078-0","volume":"19","author":"JL McQuade","year":"2018","unstructured":"McQuade JL, et al. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. Lancet Oncol. 2018;19(3):310\u201322.","journal-title":"Lancet Oncol"},{"issue":"2","key":"2689_CR22","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/ajh.24228","volume":"91","author":"S Tavitian","year":"2016","unstructured":"Tavitian S, et al. Impact of obesity in favorable-risk AML patients receiving intensive chemotherapy. Am J Hematol. 2016;91(2):193\u20138.","journal-title":"Am J Hematol"},{"issue":"12","key":"2689_CR23","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1111\/1759-7714.12870","volume":"9","author":"A Cortellini","year":"2018","unstructured":"Cortellini A, et al. Single-institution study of correlations between skeletal muscle mass, its density, and clinical outcomes in non-small cell lung cancer patients treated with first-line chemotherapy. Thorac Cancer. 2018;9(12):1623\u201330.","journal-title":"Thorac Cancer"},{"issue":"1","key":"2689_CR24","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.pan.2018.11.001","volume":"19","author":"Y Kurita","year":"2019","unstructured":"Kurita Y, et al. Sarcopenia is a reliable prognostic factor in patients with advanced pancreatic cancer receiving FOLFIRINOX chemotherapy. Pancreatology. 2019;19(1):127\u201335.","journal-title":"Pancreatology"},{"issue":"11","key":"2689_CR25","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1007\/s00432-018-2736-z","volume":"144","author":"H van Baar","year":"2018","unstructured":"van Baar H, et al. Low radiographic muscle density is associated with lower overall and disease-free survival in early-stage colorectal cancer patients. J Cancer Res Clin Oncol. 2018;144(11):2139\u201347.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"8","key":"2689_CR26","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1093\/annonc\/mdx203","volume":"28","author":"V M\u00f6bus","year":"2017","unstructured":"M\u00f6bus V, et al. German Adjuvant Intergroup Node-positive Study (GAIN): a phase III trial comparing two dose-dense regimens (iddEPC versus ddEC-PwX) in high-risk early breast cancer patients. Ann Oncol. 2017;28(8):1803\u201310.","journal-title":"Ann Oncol"},{"issue":"4","key":"2689_CR27","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s12032-014-0881-z","volume":"31","author":"JP Carroll","year":"2014","unstructured":"Carroll JP, et al. Toxicity and tolerability of adjuvant breast cancer chemotherapy in obese women. Med Oncol. 2014;31(4):881.","journal-title":"Med Oncol"},{"issue":"6","key":"2689_CR28","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1080\/0284186X.2019.1585942","volume":"58","author":"W Bouleftour","year":"2019","unstructured":"Bouleftour W, et al. Obesity and chemotherapy administration: between empiric and mathematic method review. Acta Oncol. 2019;58(6):880\u20137.","journal-title":"Acta Oncol"},{"issue":"8","key":"2689_CR29","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/nrclinonc.2013.108","volume":"10","author":"GH Lyman","year":"2013","unstructured":"Lyman GH, Sparreboom A. Chemotherapy dosing in overweight and obese patients with cancer. Nat Rev Clin Oncol. 2013;10(8):451\u20139.","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"2689_CR30","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1093\/annonc\/mdw315","volume":"27","author":"J Furlanetto","year":"2016","unstructured":"Furlanetto J, et al. Higher rate of severe toxicities in obese patients receiving dose-dense (dd) chemotherapy according to unadjusted body surface area: results of the prospectively randomized GAIN study. Ann Oncol. 2016;27(11):2053\u20139.","journal-title":"Ann Oncol"},{"issue":"3","key":"2689_CR31","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jgo.2017.11.007","volume":"9","author":"VA Morrison","year":"2018","unstructured":"Morrison VA, et al. The impact of actual body weight-based chemotherapy dosing and body size on adverse events and outcome in older patients with breast cancer: Results from Cancer and Leukemia Group B (CALGB) trial 49907 (Alliance A151436). J Geriatr Oncol. 2018;9(3):228\u201334.","journal-title":"J Geriatr Oncol"},{"issue":"9","key":"2689_CR32","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.clon.2016.02.003","volume":"28","author":"H Lote","year":"2016","unstructured":"Lote H, et al. Febrile neutropenia rates according to body mass index and dose capping in women receiving chemotherapy for early breast cancer. Clin Oncol (R Coll Radiol). 2016;28(9):597\u2013603.","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"3","key":"2689_CR33","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.ejca.2006.10.013","volume":"43","author":"P Jenkins","year":"2007","unstructured":"Jenkins P, Elyan S, Freeman S. Obesity is not associated with increased myelosuppression in patients receiving chemotherapy for breast cancer. Eur J Cancer. 2007;43(3):544\u20138.","journal-title":"Eur J Cancer"},{"issue":"6","key":"2689_CR34","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1158\/1078-0432.CCR-09-2636","volume":"16","author":"FA Sinicrope","year":"2010","unstructured":"Sinicrope FA, et al. Obesity is an independent prognostic variable in colon cancer survivors. Clin Cancer Res. 2010;16(6):1884\u201393.","journal-title":"Clin Cancer Res"},{"issue":"9491","key":"2689_CR35","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/S0140-6736(05)67110-3","volume":"366","author":"M Colleoni","year":"2005","unstructured":"Colleoni M, et al. Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index. Lancet. 2005;366(9491):1108\u201310.","journal-title":"Lancet"},{"key":"2689_CR36","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejca.2018.05.004","volume":"99","author":"G Stocker","year":"2018","unstructured":"Stocker G, et al. Clinical consequences of chemotherapy dose reduction in obese patients with stage III colon cancer: a retrospective analysis from the PETACC 3 study. Eur J Cancer. 2018;99:49\u201357.","journal-title":"Eur J Cancer"},{"issue":"3","key":"2689_CR37","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1093\/annonc\/mdr277","volume":"23","author":"P Chambers","year":"2012","unstructured":"Chambers P, et al. Chemotherapy dose reductions in obese patients with colorectal cancer. Ann Oncol. 2012;23(3):748\u201353.","journal-title":"Ann Oncol"},{"issue":"4","key":"2689_CR38","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1200\/JCO.2004.07.121","volume":"22","author":"JA Meyerhardt","year":"2004","unstructured":"Meyerhardt JA, et al. Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114. J Clin Oncol. 2004;22(4):648\u201357.","journal-title":"J Clin Oncol"},{"issue":"3","key":"2689_CR39","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/cncr.11544","volume":"98","author":"JA Meyerhardt","year":"2003","unstructured":"Meyerhardt JA, et al. Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma. Cancer. 2003;98(3):484\u201395.","journal-title":"Cancer"},{"issue":"1","key":"2689_CR40","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ygyno.2009.03.010","volume":"114","author":"J Schwartz","year":"2009","unstructured":"Schwartz J, Toste B, Dizon DS. Chemotherapy toxicity in gynecologic cancer patients with a body surface area (BSA)>2 m2. Gynecol Oncol. 2009;114(1):53\u20136.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"2689_CR41","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ygyno.2014.01.030","volume":"133","author":"G Au-Yeung","year":"2014","unstructured":"Au-Yeung G, et al. Impact of obesity on chemotherapy dosing for women with advanced stage serous ovarian cancer in the Australian Ovarian Cancer Study (AOCS). Gynecol Oncol. 2014;133(1):16\u201322.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"2689_CR42","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ygyno.2015.04.040","volume":"138","author":"J Hansen","year":"2015","unstructured":"Hansen J, et al. The effect of weight-based chemotherapy dosing in a cohort of gynecologic oncology patients. Gynecol Oncol. 2015;138(1):154\u20138.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"2689_CR43","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.ygyno.2008.02.023","volume":"109","author":"JD Wright","year":"2008","unstructured":"Wright JD, et al. Carboplatin dosing in obese women with ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2008;109(3):353\u20138.","journal-title":"Gynecol Oncol"},{"issue":"5","key":"2689_CR44","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1093\/annonc\/mdm606","volume":"19","author":"SV Barrett","year":"2008","unstructured":"Barrett SV, et al. Does body mass index affect progression-free or overall survival in patients with ovarian cancer? Results from SCOTROC I trial. Ann Oncol. 2008;19(5):898\u2013902.","journal-title":"Ann Oncol"},{"issue":"5","key":"2689_CR45","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/jnci\/87.5.361","volume":"87","author":"MS Georgiadis","year":"1995","unstructured":"Georgiadis MS, et al. Obesity and therapy-related toxicity in patients treated for small-cell lung cancer. J Natl Cancer Inst. 1995;87(5):361\u20136.","journal-title":"J Natl Cancer Inst"},{"key":"2689_CR46","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.lungcan.2016.11.017","volume":"104","author":"VK Lam","year":"2017","unstructured":"Lam VK, et al. Obesity is associated with long-term improved survival in definitively treated locally advanced non-small cell lung cancer (NSCLC). Lung Cancer. 2017;104:52\u20137.","journal-title":"Lung Cancer"},{"issue":"3","key":"2689_CR47","volume":"10","author":"W Wu","year":"2015","unstructured":"Wu W, et al. Association of body composition with outcome of docetaxel chemotherapy in metastatic prostate cancer: a retrospective review. PLoS One. 2015;10(3): e0122047.","journal-title":"PLoS One"},{"key":"2689_CR48","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1016\/j.clnesp.2016.04.001","volume":"13","author":"SJ Cushen","year":"2016","unstructured":"Cushen SJ, et al. Impact of body composition parameters on clinical outcomes in patients with metastatic castrate-resistant prostate cancer treated with docetaxel. Clin Nutr ESPEN. 2016;13:e39\u201345.","journal-title":"Clin Nutr ESPEN"},{"issue":"3","key":"2689_CR49","doi-asserted-by":"crossref","first-page":"541","DOI":"10.3109\/10428194.2012.717278","volume":"54","author":"A Lin","year":"2013","unstructured":"Lin A, et al. Influence of obesity on efficacy and toxicity of induction chemotherapy in patients with newly diagnosed acute myeloid leukemia. Leuk Lymphoma. 2013;54(3):541\u20136.","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"2689_CR50","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1002\/ajh.23530","volume":"88","author":"CM Wenzell","year":"2013","unstructured":"Wenzell CM, et al. Outcomes in obese and overweight acute myeloid leukemia patients receiving chemotherapy dosed according to actual body weight. Am J Hematol. 2013;88(10):906\u20139.","journal-title":"Am J Hematol"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02689-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-02689-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02689-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T11:53:22Z","timestamp":1759146802000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-02689-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,6]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2689"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-02689-8","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,6]]},"assertion":[{"value":"3 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article has been updated to correct the corresponding author information.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This case report was approved by the Medical Ethics Committee of the Fourth Hospital of Hebei Medical University (approval number 2022KS008).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}},{"value":"Informed consent has been obtained from all subjects and\/or their legal guardian(s) for publication of identifying information\/images in an online open-access publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent to publish"}},{"value":"Written informed consent was obtained from the patient before submission of this article.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"1020"}}